Fundraising Fox
Michihiko Wada
InvestorChief Regulatory and Development Officer at Newton Biocapital
Tokyo, Tokyo, Japan
Find your path to Michihiko
300 people in our graph can introduce you to Michihiko.
Each arrow is one introduction. Sign up to fill in the first one.
Ask Ken Horne to introduce you to Michihiko
You →Ken · together at Japan Agency for Medical Research and Development (2026) →Michihiko
Ask Jamie Chen to introduce you to Michihiko
You →Jamie · 6 people · together at Newton Biocapital →Michihiko
Ask Sam Okafor to introduce you to Michihiko
You →Sam · 3 people · together at ソフトバンク →Michihiko
Sign up to find every way you can get introduced to Michihiko
- Your email: the people you already email who know Michihiko
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Michihiko
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
About
Michihiko Wada serves as Program Officer for the Strengthening Program for Pharmaceutical Startup Ecosystem at the Japan Agency for Medical Research and Development, and holds the position of Corporate Development & Regulatory Officer at Newton BioCapital Partners. He was involved in obtaining approval for Strensiq from Japan's Ministry of Health, Labour and Welfare on July 3, 2015, the first such approval globally.
Experience
- Japan Agency for Medical Research and DevelopmentProgram Officer, Strengthening Program for Pharmaceutical Startup Ecosystemcurrent2025 — presentTokyo, Tokyo, Japan
- NEWTON BIOCAPITALCorporate Development & Regulatory Officercurrent2024 — presentTokyo
- NEWTON BIOCAPITALAdvisor, Medical & Clinical science s2022 — 2024Tokyo, Japan
- NEWTON BIOCAPITALIndependent Board of Director2020 — 2022Based in Tokyo
- Clinical &Translational Research Center, Keio UniversityProfessor2024 — 2025Tokyo, Japan
- Clinical and Translational Research Center, Keio UniversityProfessor2019 — 2024Shinanomachi 35, Shinjuku-ku, TOKYO
- ソフトバンク医学顧問2021 — 2023Tokyo, Japan
- Translational Research Center for Medical InnovationFellow2019 — 2020
- Alexion Pharmaceuticals, Inc.Vice President, Head of R&D Tokyo2014 — 2019
- Foundation of Biomedical and Research InnovationAdviser2012 — 2018
- Alexion Pharmaceuticals JapanHead of Clinical Development2012 — 2017
- Kanazawa Advanced Medical CenterDirector of Personalised Medicine2010 — 2012
- Bayer HealthCare JapanHead of Oncology & Speciality Medicine, Clinical Development2007 — 2010
- Kobe City General HospitalChief Surgeon in HepatoBiliary Pancreatic Surgery2001 — 2007
- Institute of Biomedical and Research Innovation HospitalSurgical Fellow2001 — 2007
- Kyoto University, Dept. of Surgery, Div. of Hepatobiliary Pancreatic Surgery and TransplantationAssistant Professor2000 — 2001
- Vanderbilt University Medical Centerpost-doctoral Fellow in Surgery1998 — 2000
Skills & more
+12 more
MedicineHospitalsR&DHealthcareDrug DevelopmentRegulatory AffairsGCPResearchStrategic PlanningPersonal DevelopmentStrategyPharmaceutical IndustryFrom Michihiko's professional profile.
Colleagues at Newton Biocapital
Frequently asked questions
- Who is Michihiko Wada?
- Michihiko Wada serves as Program Officer for the Strengthening Program for Pharmaceutical Startup Ecosystem at the Japan Agency for Medical Research and Development, and holds the position of Corporate Development & Regulatory Officer at Newton BioCapital Partners. He was involved in obtaining approval for Strensiq from Japan's Ministry of Health, Labour and Welfare on July 3, 2015, the first such approval globally.
- Where does Michihiko Wada work?
- Michihiko Wada is Chief Regulatory and Development Officer at Newton Biocapital.
- Where did Michihiko Wada go to school?
- Michihiko Wada studied at Kyoto University (PhD, Surgical Oncology).
Same school
Also attended Kyoto University67
+ 61 more
Shared employers
Also worked at Japan Agency for Medical Research and Development1
Also worked at NEWTON BIOCAPITAL5
Also worked at ソフトバンク23
+ 17 more
Also worked at Alexion Pharmaceuticals, Inc.31
+ 25 more